Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) · Sponsor: Novartis Pharmaceuticals
This study evaluates iptacopan effectiveness and safety in routine clinical practice, with a focus on hematological response, transfusion avoidance, and patient-reported outcomes. The primary objective of the REAL-CARE study is to is to assess the long-term hematological response following iptacopan initiation. This will be assessed through the absolute change in hemoglobin (Hb) levels at 12 months post-initiation, and the proportion of patients who remain free from red blood cell (RBC) transfusions, prescribed as per local requirement and based on Investigator's judgment, from Day 14 through Month 12 after starting iptacopan.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Alessandria, AL, Italy | Recruiting |
| Novartis Investigative Site | Avellino, AV, Italy | Recruiting |
| Novartis Investigative Site | Brescia, BS, Italy | Recruiting |
| Novartis Investigative Site | Florence, FI, Italy | Recruiting |
| Novartis Investigative Site | Genova, GE, Italy | Recruiting |
| Novartis Investigative Site | Milan, MI, Italy | Recruiting |
| Novartis Investigative Site | Milan, MI, Italy | Recruiting |
| Novartis Investigative Site | Palermo, PA, Italy | Recruiting |
| Novartis Investigative Site | Roma, RM, Italy | Recruiting |
| Novartis Investigative Site | Roma, RM, Italy | Recruiting |
| Novartis Investigative Site | Torino, TO, Italy | Recruiting |
| Novartis Investigative Site | Bassano del Grappa, VI, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07229235